SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions for Sickle Cell Disease

CLINICAL DEVELOPMENT SOLUTIONS TO IMPROVE SICKLE CELL DISEASE RESEARCH

While it was first described more than 100 years ago, sickle cell disease (SCD) remains an area with limited therapeutic options. Your SCD research program represents hope to millions of patients living with the effects of this disease. That's why we tailored our SmartSignals™ solutions to address specific research challenges so you can deliver new and better treatment options.

SIMPLIFY SITE-BASED PROs

Your sickle cell disease research protocol likely includes several patient-reported outcome assessments for safety, efficacy, or patient function measures. Signant's eCOA solution, supported by a project team experienced in this chronic condition, helps simplify site-based PRO assessment administration while improving the quality and reliability of endpoint data.

OPTIMIZE THE SCD PATIENT DIARY

Gather complete, accurate, and timely data from participants - our team of technical and eCOA science specialists will help you design a clinically meaningful diary and implement it on provisioned or BYOD devices. Pair with our engagement solution to ensure participants provide timely entries.

EXPAND YOUR REACH

Meet enrollment goals by conducting your research in more countries, enabled by proven technologies. With Signant's end-to-end solutions, you can obtain informed consent, enroll and randomize participants, and collect COA data remotely. Plus, our secure Telemedicine platform helps study teams and participants connect when site visits are not required.

REDUCE PARTICIPANT BURDENS

SCD pain crises can make everyday tasks difficult for patients. Simplify the clinical trial participation experience by providing tools like eConsent and Telemedicine that reduce the need for complicated form completions or site visits. As an added bonus, sites benefit by maintaining up-to-date ICFs and consulting with patients remotely.

GAIN EXPERT GUIDANCE

From consulting on outcome measure selection to customized participant diary design, Signant's in-house experts will help you navigate common SCD research challenges from study launch to closeout. Talk through your protocol with our experienced clinical science and medicine experts.

DIGITALIZE THE PROCESS

Any of our clinical research technology solutions and services can be used individually, but when you combine them, your study will be optimized from end-to-end to deliver accurate endpoint data.

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for SCD patients everywhere.

SIGNANT'S HEMATOLOGY CLINICAL TRIAL EXPERIENCE

Phases III IV



43 Languages

530+ Sites

34 Countries

10,000 Patients

122 Studies

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

Scientific Consulting & Advisory

Telemedicine

eConsent

RTSM

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS